Gastric motility drug market - local drug companies crowding into top 10 of the world: a closer look at five major varieties

Source: pharmaceutical economic news 2016-11-03 gastric motility (gastromotility), also known as gastrointestinal motility drugs, is a functional gastrointestinal drug that can increase gastrointestinal motility, which is mainly used for dyspepsia and gastroesophageal reflux In recent years, people 's living standards are increasing, but due to the lack of attention to diet habits and other factors, there are more and more people suffering from stomach discomfort, bloating, anorexia and other gastrointestinal diseases According to statistics, the incidence rate of stomach diseases in China is about 7% to 10%, and the incidence is about 300 million people, ranking the highest in the world Therefore, gastric motility drugs have been widely used in clinical practice 1 Gastric motility drugs, which account for the largest share of functional gastrointestinal drugs in the world, are an important class of functional gastrointestinal drugs According to statistics, as of 12 months in March 2016 (April 2015 to March 2016, the same below), the global factory value of functional gastrointestinal drug preparations was about 3.47 billion US dollars, which increased by - 5% and 6% respectively on a year-on-year basis, calculated at floating exchange rate and fixed exchange rate (the same below), including 1.34 billion US dollars for gastric motility drugs, which increased by - 10% and 1% respectively on a year-on-year basis Gastric motility drugs are the largest market share of functional gastrointestinal drugs, accounting for 38% (US $1.34 billion / US $3.47 billion) The market share of various functional gastrointestinal diseases is shown in Figure 1 According to statistics, the Japanese market is the first As of March 2016, the factory value of gastric motility drugs in Asia / Africa / Australia was about 673 million US dollars It is the largest regional market in the world, with a year-on-year growth of - 8% and 0% In the Asian / African / Australian regional market, Japan's gastric motility drug market is the first, about 186 million US dollars, with a year-on-year growth of - 14% and - 5%; the South Dynasty fresh food market is the second, about 122 million US dollars, with a year-on-year growth of - 14% and - 6%; China's third, about 118 million US dollars, with a year-on-year growth of - 1% and 2% Unlike most other types of drugs, North America's gastric motile drug market is the smallest with only US $40 million, an increase of - 4% and 1% respectively year on year The market structure is a low concentration competitive Johnson & Johnson company, which is the world's leading manufacturer of gastric motility drugs As of March 2016, the annual sales volume of preparations was about 90 million US dollars, ranking first in the world's leading sales companies of gastric motility drugs (see Table 1) from table 1, it can be seen that Cr4 = 21.6% > > the world's leading four gastric motility drug companies have strong regional characteristics, with Asia dominating the market, and domperidone (Domperidone Tablets), the old star drug, still ranks first in global sales There are many kinds of compound preparations of gastric motility drugs, which have not formed large-scale sales At present, single prescription gastric motility drugs are still the main sales varieties in the market at home and abroad Although the global gastric motility drug market has declined and slightly increased year-on-year (2015.4-2016.3 and 2014.4-2015.3) after converting US dollars at floating and fixed exchange rates, it should be noted that the US dollar index has increased by about 12% during this period, and most currencies, especially the euro countries, have more devaluation after converting US dollars Therefore, the overall gastric motility drug market shows normal development.